Island Pharma Jumps After Emergency Use Approval for Ebola Drug The recent approval of Island Pharmaceuticals' experimental antiviral galidesivir for emergency use in patients with the Bundibugyo strain of Ebola in Uganda has sent shockwaves through the healthcare community.
On closer inspection, this appears to be more than just a routine regulatory clearance – it's a desperate attempt by Island Pharma to mitigate the escalating crisis.
The High Risk, High Reward Gamble The approval comes at a critical juncture in the Ebola outbreak in Uganda, where cases are rising and containment efforts are faltering.